Iberdomide (CC-220), marketed as Zenbexus by Bristol-Myers Squibb (BMS), received accelerated FDA approval on August 13, 2026, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
[More Info] 📰 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone

Iberdomide is a cereblon (CRBN) modulator that binds CRBN with higher affinity than lenalidomide and pomalidomide, leading to more potent and extensive degradation of the transcription factors Ikaros and Aiolos. Its enhanced activity is associated with additional interactions with CRBN, highlighting the potential of stronger E3 ligase binding to improve substrate degradation in targeted protein degradation.
[More Info] 📰 https://doi.org/10.1021/acs.jmedchem.6b01921

🛒 CLICK HERE to try BLDpharm's CRBN lignads in your research, or contact 📧 [email protected] for inquiries.